Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Rising rates of obesity are fueling the epidemic.
Currently, there are no pharmacological treatments for liver fibrosis related to non-alcoholic steatohepatitis.
There is perhaps a nine-year lag between increases in obesity and a rise in additions to the NASH-related transplant waiting list.
Interestingly, the drugs themselves, not just the act of curing the virus, were tied to a lower diabetes risk in a recent large study.
Non-alcoholic fatty liver disease can lead to more severe, potentially fatal liver diseases, including cirrhosis.
Liver cancer rates and deaths have doubled in the United States, Canada, Australia and United Kingdom.
As pharmaceutical companies race to develop treatments for NASH, they find one thing is missing: willing test subjects.
This finding calls into question the importance of the one differentiation between alcoholic and non-alcoholic fatty liver disease.
The chronic condition has been linked to an increased risk for diabetes, high blood pressure, high cholesterol and cardiovascular disease.
In observance of Liver Cancer Awareness Month, a collection of stories about liver disease, hepatitis, cancer and obesity
Low nighttime oxygen could cause an imbalance of free radicals in the body, impeding the liver’s ability to counteract their harmful effects
New research challenges current theories about the condition’s links to obesity.
The center aims to develop new tests to diagnose non-alcoholic fatty liver disease, and potentially develop treatments where none exist.
Hepatitis C dramatically raises the risk of liver cancer. Here are some tips to lower that increased risk.
The condition can cause liver scarring, called cirrhosis, and even liver failure.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.